Planet Fitness, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – PLNT

PR Newswire

LOS ANGELES, Aug. 10, 2026 /PRNewswire/ — The DJS Law Group reminds investors of a class action lawsuit against Planet Fitness, Inc. (“Planet Fitness” or “the Company”) (NYSE: PLNT) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of PLNT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: November 6, 2025 to May 6, 2026

DEADLINE: September 14, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Planet Fitness overstated its ability to pick up new members using its existing marketing campaigns. The Company failed to effectively roll out its national Black Card price increase. Based on these facts, Planet Fitness’s public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/planet-fitness-inc-sued-for-securities-law-violations—contact-the-djs-law-group-to-discuss-your-rights–plnt-302846950.html

SOURCE DJS Law Group LLP

Tuya to Report Second Quarter 2026 Financial Results on August 24, 2026 Eastern Time

PR Newswire

SANTA CLARA, Calif., Aug. 10, 2026 /PRNewswire/ — Tuya Inc. (“Tuya” or the “Company”) (NYSE: TUYA; HKEX: 2391), a global leading AI cloud platform service provider, today announced that it will report its second quarter 2026 unaudited financial results after the market closes on Monday, August 24, 2026.

Tuya’s management will hold a conference call at 08:30 P.M. Eastern Time on Monday, August 24, 2026 (08:30 A.M. Hong Kong Time on Tuesday, August 25, 2026) to discuss the financial results. In advance of the conference call, all participants must use the following links to complete the online registration process. Upon registering, each participant will receive the dial-in information and a unique PIN (personal access code) to join the call as well as an email confirmation with the details.

Participants Online Webcast Registration: https://edge.media-server.com/mmc/p/x8phnjqd

Participants Call Registration: https://register-conf.media-server.com/register/BI2992f21177c7423c83ce142eb2ef031c

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at https://ir.tuya.com.

About Tuya Inc.

Tuya Inc. (NYSE: TUYA; HKEX: 2391) is a global leading AI cloud platform service provider with a mission to build an AI developer ecosystem and enable everything to be smart. Tuya has pioneered a purpose-built AI cloud platform with cloud and generative AI capabilities that delivers a full suite of offerings, including Platform-as-a-Service, or PaaS, AI application & others and Smart home & robot products for developers of smart device, commercial applications, and industries. Through its AI developer platform, Tuya has activated a vibrant global developer community of brands, OEMs, AI agents, system integrators and independent software vendors to collectively strive for smart solutions ecosystem embodying the principles of green and low-carbon, security, high efficiency, agility, and openness.

Investor Relations Contact

Tuya Inc.
Investor Relations
Email: [email protected]

HL Strategy
Haiyan LI-LABBE
Email: [email protected]

Piacente Financial Communications
China Tel: +86-10-6508-0677
U.S. Tel: +1-212-481-2050
Email: [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/tuya-to-report-second-quarter-2026-financial-results-on-august-24-2026-eastern-time-302846955.html

SOURCE Tuya Inc.

KBR Awarded $208 Million Army Contract to Advance Next Generation Tactical Munitions

HOUSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) — KBR (NYSE: KBR) announced today Trinzic, the planned spin-off of its Mission Technology Solutions business, has secured an estimated $208 million cost-plus-fixed-fee task order to continue supporting the U.S. Army’s Tactical Aviation and Ground Munitions (TAGM) portfolio, a centerpiece of the Army’s precision strike and aviation modernization efforts. The five-year recompete extends KBR’s role as a prime contractor on one of the Army’s highest lethality priorities, and it reinforces the company’s long-standing leadership in defense technology modernization for the U.S. and its allies.

The task order was awarded under the One Acquisition Solution for Integrated Services Plus (OASIS+) government-wide contract vehicle. KBR will provide end-to-end support across the full lifecycle, from advanced engineering and rapid prototyping to modernization, foreign military sales and global logistics. This integrated approach accelerates the development, fielding and sustainment of TAGM’s portfolio of combat-proven weapon systems, including HELLFIRE, Joint Air-to-Ground Missile (JAGM), Javelin and Tube-launched, Optically-tracked, Wireless-guided (TOW) missiles, Hydra Rockets and Long-Range Precision Munitions (LRPM) as well as advanced rocket and containerized weapons platforms. These systems remain in high demand across global theaters as threat environments increasingly evolve.

“This award reflects the Army’s trust in KBR to move quickly and handle complexity without losing focus on the mission,” said Jay Lennon, President of Mission Technology Solutions. “For more than 25 years, KBR has helped take the Army’s most important precision weapons from concept to combat readiness, shortening development timelines and accelerating delivery to the field.”

The award directly supports the Army’s top modernization priorities, including multi-domain operations, Army Aviation lethality, and Launched Effects and low-cost, effective Counter-Unmanned Aircraft System (C-UAS) capabilities.

As the Army continues to rely on accelerated acquisition pathways to prototype and field new capabilities faster, KBR’s commitment as a trusted partner ensures delivery at Speed to Mission ImpactSM through deep engineering expertise, advanced digital tools and global execution capability. These strengths position the company as a trusted partner for rapid defense innovation and sustained combat readiness.

About KBR

We deliver science, technology and engineering solutions to governments and companies around the world. KBR employs approximately 37,000 people worldwide with customers in more than 85 countries and operations in over 28 countries. KBR is proud to work with its customers across the globe to provide technology, value-added services, and long-term operations and maintenance services to ensure consistent delivery with predictable results. At KBR, We Deliver.

Visit www.kbr.com

About Trinzic

KBR’s Mission Technology Solutions business is expected to be spun off as an independent public company in January 2027 and will then operate under the new name Trinzic. The name is inspired by the word intrinsic, reflecting the essential capabilities, deep expertise, speed and trusted performance that have defined the business for decades. Trinzic will enter the market as a global company and partner to customers supporting some of the highest priority missions across national security, human performance, global operations and space. Trinzic will launch with more than $5 billion in annual revenue, established partnerships and contracts, 18,000 employees and a global footprint.    

Forward Looking Statements

The statements in this press release that are not historical statements, including statements regarding KBR and Trinzic’s defense technology modernization capabilities and planned spin-off of Trinzic from KBR, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks, uncertainties and assumptions, many of which are beyond the company’s control, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks, uncertainties and assumptions include, but are not limited to, those set forth in the company’s most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks and other U.S. Securities and Exchange Commission filings, which discuss some of the important risks, uncertainties and assumptions that the company has identified that may affect its business, results of operations and financial condition. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

For further information, please contact:


Investors


Rachael Goldwait
Vice President, Investor Relations
713-753-5082
[email protected]


Media


Philip Ivy
Vice President, Global Communications and Marketing
713-753-3800
[email protected]



Barrick and Newmont Reach Agreement Regarding Nevada Gold Mines Joint Venture

Amended JV Agreement Includes Contribution of Excluded Properties and Concludes All Outstanding Disputes Between Parties

Newmont Has Provided Its Consent to Barrick’s Proposed North American IPO

Agreement Positions Both Companies to Maximize Value of the Joint Venture

TORONTO and DENVER, Aug. 10, 2026 (GLOBE NEWSWIRE) — Barrick Mining Corporation (TSX: ABX, NYSE: B) (“Barrick”) and Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) have reached an agreement under which excluded properties, including Barrick’s Fourmile and Newmont’s Fiberline and Mike developments, will be contributed into the Nevada Gold Mines (NGM) joint venture. The agreement concludes all outstanding disputes between the parties related to the NGM joint venture.

With the resolution of all outstanding disputes and contribution of excluded properties, Newmont has provided its consent to Barrick’s proposed IPO of its North American gold assets.

The agreement includes enhanced governance provisions under a modernized joint venture agreement and provides for consideration of $1.95 billion from Newmont to Barrick to reflect the contribution of excluded properties into the joint venture.

This agreement positions both parties to maximize the value of the joint venture. Newmont and Barrick will continue working together to improve NGM’s safety and performance, unlock the full value these assets are capable of delivering, and ensure the long-term success of the joint venture for the benefit of all stakeholders.

About Barrick Mining Corporation

Barrick is a leading global mining, exploration, and development company. With one of the largest portfolios of world-class and long-life gold and copper assets in the industry, Barrick’s operations and projects span 17 countries and five continents. Barrick is also the largest gold producer in the United States. We create real, long-term value for all stakeholders through responsible mining, strong partnerships, and a disciplined approach to growth. Barrick shares trade on the New York Stock Exchange under the symbol ‘B’ and on the Toronto Stock Exchange under the symbol ‘ABX’.

About Newmont

Newmont is the world’s leading gold company and a producer of copper, zinc, lead, silver and molybdenum, providing the metals the world needs for today and tomorrow. Founded in 1921 and publicly traded since 1925, Newmont is the only gold producer listed in the S&P 500 Index and is widely recognized for its principled environmental, social, and governance practices. At Newmont, our purpose is to unearth value sustainably to advance lives. To learn more, visit www.newmont.com.


Barrick Contacts

Investor Relations Contact

Emily Chieng
[email protected]

Media Contact
Dan Wilner [email protected]


Newmont Contacts

Investor Contact – Global

Neil Backhouse
[email protected]

Media Contact – Global
Shannon Brushe
[email protected]



Cautionary Statement on Forward-Looking Information

Certain information contained in this press release constitutes “forward-looking statements” and “forward-looking information” within the meaning of applicable U.S. and Canadian securities laws. Forward-looking statements include, without limitation, statements regarding the expected contribution of Barrick’s Fourmile and Newmont’s Fiberline and Mike developments into the Nevada Gold Mines joint venture; the consideration to be provided by Newmont to Barrick; the amended joint venture agreement and related governance provisions; the resolution of outstanding disputes; Newmont’s consent to Barrick’s proposed IPO of its North American gold assets; and the parties’ ability to maximize value, improve safety and performance, and support the long-term success of the joint venture.

Forward-looking statements are based on estimates and assumptions that are inherently subject to business, economic, legal, regulatory and other risks and uncertainties. These include risks relating to the completion and timing of the contemplated property contributions; required approvals, consents and conditions; the realization of anticipated benefits from the amended joint venture agreement, enhanced governance, dispute resolution and property contributions; changes in the value, development prospects or performance of the contributed properties; risks associated with jointly controlled assets and joint venture partners; mining operations, permitting, environmental, health and safety matters, community and stakeholder relations; the proposed IPO, including timing, structure, market conditions, approvals and listing requirements; transaction costs; commodity prices, exchange rates, inflation, interest rates, capital markets and broader macroeconomic, geopolitical, legal, tax and regulatory conditions.

Actual results may differ materially from those expressed or implied in forward-looking statements. Readers should not place undue reliance on such statements, which are not guarantees of future performance and are qualified by these cautionary statements. Reference is made to Barrick’s and Newmont’s most recent annual and other reports filed with the SEC and applicable Canadian or other securities regulatory authorities for a more detailed discussion of relevant risks.

Barrick and Newmont disclaim any obligation to update or revise forward-looking statements, except as required by applicable law.



Barrick Reports Second Quarter 2026 Results

Agreement with Newmont resolves all disputes; Newmont’s consent to Barrick’s American IPO provides substantial flexibility and value

Barrick achieves third straight quarter of strong operational and financial results

  • Barrick reached an agreement with Newmont to expand the assets in the Nevada Gold Mines Joint Venture. Both companies are vending in their excluded properties early: Fourmile from Barrick; Mike and Fiberline from Newmont, creating a nearly 100-million-ounce gold complex in Nevada. Newmont will pay Barrick a top-up payment of $1.95 billion cash within thirty days. The agreement resolves all outstanding disputes related to NGM. Newmont has consented to Barrick’s IPO of its North American gold assets, providing great structural flexibility and value.
  • Q2 gold production increased 11% over Q1 to 796,000 ounces1, exceeding guidance of 730,000–770,000 ounces1, driven by the ahead-of-schedule ramp-up at Loulo-Gounkoto, a faster-than-expected recovery at Pueblo Viejo following planned Q1 maintenance, and record underground tonnes at Cortez as Goldrush continues to ramp up.
  • Strong cost discipline across mining and processing kept costs within guidance despite fuel price pressures, with gold cost of sales of $1,993 per ounce, and AISC3 of $1,866 per ounce.
  • Operating cash flow of $1.70 billion for the quarter increased 28% year-on-year.
  • Net earnings of $1.22 billion for the quarter increased 50% year-on-year, net earnings per share of $0.73 rose 55% year-on-year, and adjusted net earnings per share3 of $0.82 was up 74% year-on-year.
  • The North American IPO remains on track for expected completion by year end. Mark Hill will be the CEO of the new company upon separation. 
  • Full year production and cost guidance unchanged; total attributable capital expenditure reduced to $3.8 billion–$4.2 billion.
  • $0.175 quarterly dividend declared and $1.2 billion in share buybacks during the quarter, increasing shareholder returns by 242% year-on-year to $1.50 billion.

All amounts expressed in U.S. dollars

TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) — Barrick Mining Corporation (NYSE:B)(TSX:ABX) (“Barrick” or the “Company”) today reported second quarter operating and financial results for the period ended June 30, 2026. Barrick produced 796,000 ounces1 of gold and 56,000 tonnes1 of copper in the quarter. The Company generated $5.29 billion in revenue, $1.70 billion in operating cash flow, $1.12 billion in attributable operating cash flow3, and $141 million in attributable free cash flow3. Net earnings per share for the quarter were $0.73, and adjusted net earnings per share3 were $0.82—up 55% and 74%, respectively, from Q2 2025.

Mark Hill, President and Chief Executive Officer, said: “We achieved an historic agreement with Newmont. Newmont has consented to the IPO and the parties have agreed to expand NGM with the early vend-in of our excluded properties, as well as settling all disputes. Through this agreement with our joint venture partner, we have substantially extended the asset base, and provided greater flexibility and value.”

Mark Hill continued: “We delivered our third quarter in a row with excellent operational and financial performance. We beat the top end of our gold production guidance and generated much higher earnings and cash flow than a year ago. We also advanced our growth pipeline, with good progress at Lumwana and Fourmile. Most importantly, we remained focused on improving safety across the business, including $90 million invested in safety technology this year. Our priorities for the second half of the year remain the same: continue to drive tangible improvements in our safety performance, improve operational consistency and deliver our full-year production and cost guidance, advance our growth projects on time and on budget, and launch the IPO of our extraordinary North American gold business by the end of the year. With a strong balance sheet, high-quality assets, and disciplined execution, we remain well positioned to deliver on our plans for 2026 and continue creating long-term value for shareholders.”

Mark Hill concluded: “We are on track to complete the IPO of our North American gold assets by the end of this year. We are excited to launch a pure play gold company with high-quality, long-life assets exclusively in low-risk jurisdictions.The cooperation agreement with Newmont expands the Nevada complex to nearly 100-million-ounces, and the agreement gives us great flexibility and value.”

Operational Highlights

Barrick continued to improve safety performance through visible leadership, consistent engagement, and a stronger focus on critical risk management.

Gold production in the second quarter totaled 796,000 ounces1, exceeding the guidance range of 730,000–770,000 ounces1. Three primary factors drove our performance: the ahead-of-schedule restart of Loulo-Gounkoto; a faster-than-expected recovery at Pueblo Viejo following planned Q1 maintenance; and record underground tonnes mined at Cortez, driven by the continued ramp-up of Goldrush. Gold cost of sales (“COS”)2 for Q2 was $1,993 per ounce, compared to COS2 of $1,654 in Q2 2025, primarily due to lower grades processed at Carlin, Cortez, and North Mara; higher fuel costs across the operations; and higher royalties associated with the stronger realized gold price3. Total cash costs (“TCC”)3 were $1,426 per ounce, compared to $1,239 in the prior-year quarter. All-in sustaining costs (“AISC”)3 were $1,866 per ounce, up 11% compared to Q2 2025.

Copper production decreased 5% year-on-year to 56,000 tonnes1 in the second quarter in line with plan. Copper COS4 of $3.39 per pound, C1 cash costs3 of $2.47 per pound, and AISC3 of $3.95 per pound, were up 32%, 37% and 36%, respectively, compared to the prior-year period. Higher royalties associated with the stronger realized copper price3, together with higher fuel prices across the operations, drove the cost increases.

Financial Highlights

A significant increase in earnings year-on-year was driven by higher realized gold and copper prices3. Net earnings totaled $1.22 billion ($0.73 per share), and adjusted net earnings3 totaled $1.36 billion ($0.82 per share), compared to net earnings of $0.81 billion ($0.47 per share), and adjusted net earnings3 of $0.80 billion ($0.47 per share) in the prior year quarter. Attributable adjusted EBITDA3 for the quarter totaled $2.55 billion, an increase of 51% year-over-year, with an attributable adjusted EBITDA margin3 of 60%.

Operating cash flow, attributable operating cash flow3, and attributable free cash flow3 in the second quarter were $1.70 billion, $1.12 billion, and $141 million, respectively, compared to operating cash flow of $1.33 billion, attributable operating cash flow3 of $929 million, and attributable free cash flow3 of $212 million in Q2 2025. Revenues of $5.29 billion increased 44% from $3.68 billion in the prior-year quarter.

Key Growth Projects

The Fourmile project in Nevada continued to demonstrate its potential to become a standalone Tier One Gold Asset.5 During the quarter, the Bullion Hill decline development contract was awarded to Barminco, and key infrastructure contracts were secured, such that we expect to begin decline development in Q3 2026. Drilling activity continued to ramp up, with 20 rigs now active on site, focused on resource conversion drilling for the prefeasibility study targeted for completion in 2028. Exploration drilling is also targeting northern extensions following the winter drilling program in the south.

The Lumwana Super Pit Expansion remains on schedule, with first copper production targeted for the end of Q1 2028. During the quarter, the second lift of the mill walls and roller slab was completed, primary crusher civil works advanced, and civil construction commenced on the overland conveyor transfer towers. Most major long-lead equipment is now on site, including the mill shells and trunnions, primary crusher, and tailings thickener.

Pueblo Viejo’s expansion advanced as focus shifted toward the Naranjo tailings storage facility, with temporary water management structures permits secured and starter dam permit approval targeted for Q1 2027. Construction remains underway for Haul Roads 17 and 19, the diorite crusher, and the new effluent treatment plant, alongside ongoing engineering for the reverse osmosis plant, flotation improvement pre-feasibility work, and planned H2 2026 water management scope definition. Meanwhile, resettlement activities achieved 95% package acceptance—with over 632 homes completed, and 570 families resettled—as design work advanced on a church, a polytechnical school, and 63 government houses.

Returns to Shareholders

A quarterly dividend of $0.175 per share has been declared in respect of performance for the second quarter of 2026. The Q2 2026 dividend will be paid on September 15, 2026, to shareholders of record at the close of business on August 31, 2026.

Barrick’s dividend policy targets a total payout of 50% of attributable free cash flow3 on an annualized basis, comprised of a fixed base quarterly dividend of $0.175 per share and a performance top-up component at each year-end based on the attributable free cash flow3 during the year. The dividend paid in any given year may be higher or lower than the 50% target based on the strength of cash flow, capital needs, balance sheet considerations, and other factors.

In addition to the quarterly dividend, Barrick repurchased $1.209 billion of shares during the quarter under the previously announced $3.0 billion share repurchase program. The repurchases reflect the Company’s commitment to returning cash to shareholders and its continued confidence in the value of its assets and long-term growth prospects, including the planned North American IPO. The repurchase authorization does not oblige the Company to acquire common shares.

2026 Guidance

Barrick is on track to meet 2026 production and cost guidance, with gold production guidance continuing to be 2.90–3.25 million ounces1. Gold cost guidance for 2026—including COS2 of $1,870–$2,070 per ounce, TCC3 of $1,330–$1,470 per ounce, and AISC3 of $1,760–$1,950 per ounce—is based on a gold price assumption of $4,500 per ounce.

Copper production guidance for 2026 remains unchanged at 190,000–220,000 tonnes1 at copper COS4 of $3.05–$3.35 per pound, C1 cash costs3 of $2.20–$2.45 per pound, and AISC3 of $3.45–$3.75 per pound. Copper cost guidance is based on a copper price assumption of $5.50 per pound.

2026 cost guidance is based on an oil price (WTI) assumption of $70 per barrel. For every $10 per barrel change in the oil price, the direct impact on costs associated with diesel consumption is $12 per ounce across our gold operations, and $0.04 per pound across our copper sites.

2026 total attributable capital expenditure has been reduced to $3.8 billion–$4.2 billion, from $4.0 billion–$4.45 billion previously, primarily reflecting decreased spending at the Reko Diq project.

North American IPO

Barrick is advancing the planned initial public offering (“IPO”) of a minority stake in a newly formed company that is expected to include Barrick’s interests in, and operatorship of, its North American gold assets, Nevada Gold Mines and Pueblo Viejo, the Fourmile project, all other North American exploration properties, and the Newmont contributed assets. The new entity will be the only North American pure play gold company with high-quality, long-life assets in low-risk jurisdictions.

Barrick continues to expect to complete the IPO by the end of 2026, subject to market and other conditions and necessary approvals.

Mark Hill will be the CEO of the new company upon separation.

Presentation and Webcast

The management team will host a live webcast and presentation today at 11:00 AM ET, followed by a question-and-answer session with analysts. To join the webcast, please register here. Presentation materials will be available on Barrick’s website prior to the event, with a replay available soon after.

About Barrick Mining Corporation

Barrick is a leading global mining, exploration and development company. With one of the largest portfolios of world-class and long-life gold and copper assets in the industry, Barrick’s operations and projects span 17 countries and five continents. Barrick is also the largest gold producer in the United States. We create real, long-term value for all stakeholders through responsible mining, strong partnerships and a disciplined approach to growth. Barrick shares trade on the New York Stock Exchange under the symbol ‘B’ and on the Toronto Stock Exchange under the symbol ‘ABX’.

Investor Relations Contact

Emily Chieng

Vice President,
Investor Relations
+1 775 397 3537
[email protected]

Media Contact

Dan Wilner

Senior Vice President,
Corporate Affairs and Capital Markets
+1 437 235 7154
[email protected] 

Financial and Operating Highlights

  For the three months ended   For the six months ended
   6/30/26 3/31/26 % Change   6/30/25 % Change   6/30/26 6/30/25 % Change
Financial Results ($ millions)                    
Revenues 5,292   5,218   1 %   3,681   44 %   10,510   6,811   54 %
Cost of sales 2,395   2,099   14 %   1,878   28 %   4,494   3,663   23 %
Net earningsa 1,217   1,602   (24)%   811   50 %   2,819   1,285   119 %
Adjusted net earningsb 1,363   1,648   (17)%   800   70 %   3,011   1,403   115 %
Attributable adjusted EBITDAb 2,545   2,761   (8)%   1,690   51 %   5,306   3,051   74 %
Attributable adjusted EBITDA marginb 60 % 66 % (9)%   55 % 9 %   63 % 53 % 19 %
Minesite sustaining capital expendituresb,c 500   380   32 %   479   4 %   880   1,043   (16)%
Project capital expendituresb,c 654   570   15 %   439   49 %   1,224   708   73 %
Total consolidated capital expendituresc,d 1,189   979   21 %   934   27 %   2,168   1,771   22 %
Total attributable capital expenditurese 978   755   30 %   717   36 %   1,733   1,348   29 %
Net cash provided by operating activities 1,704   2,554   (33)%   1,329   28 %   4,258   2,541   68 %
Net cash provided by operating activities marginf 32 % 49 % (35)%   36 % (11)%   41 % 37 % 11 %
Attributable operating cash flowb 1,119   1,968   (43)%   929   20 %   3,087   1,783   73 %
Free cash flowb 515   1,575   (67)%   395   30 %   2,090   770   171 %
Attributable free cash flowb 141   1,213   (88)%   212   (33)%   1,354   435   211 %
Net earnings per share (basic and diluted) 0.73   0.96   (24)%   0.47   55 %   1.69   0.75   125 %
Adjusted net earnings (basic)b per share 0.82   0.98   (16)%   0.47   74 %   1.80   0.82   120 %
Weighted average diluted common shares (millions of shares) 1,666   1,675   (1)%   1,716   (3)%   1,671   1,721   (3)%
Debt (current and long-term) 4,682   4,726   (1)%   4,729   (1)%   4,682   4,729   (1)%
Cash and equivalents 5,927   7,131   (17)%   4,802   23 %   5,927   4,802   23 %
Debt, net of cash (1,245 ) (2,405 ) (48)%   (73 ) 1,605 %   (1,245 ) (73 ) 1,605 %

a. Net earnings represents net earnings attributable to the equity holders of the Company.
b. Further information on these non-GAAP financial measures, including detailed reconciliations, is included in the endnotes to this press release.
c. Amounts presented on a consolidated cash basis. Project capital expenditures are not included in our calculation of all-in sustaining costs.
d. Total consolidated capital expenditures also includes capitalized interest of $35 million for Q2 2026 (Q1 2026: $29 million; Q2 2025: $16 million).
e. These amounts are presented on the same basis as our guidance.
f. Represents net cash provided by operating activities divided by revenue.
   

  For the three months ended   For the six months ended
  6/30/26 3/31/26 % Change   6/30/25 % Change   6/30/26 6/30/25 % Change
Operating Results                    

Gold
                   
Gold production (thousands of ounces)a 796 719 11 %   797 0 %   1,515 1,555 (3)%
Gold sold (thousands of ounces)a 801 748 7 %   770 4 %   1,549 1,521 2 %
Market gold price ($/oz) 4,506 4,873 (8)%   3,280 37 %   4,693 3,067 53 %
Realized gold pricea,b ($/oz) 4,417 4,823 (8)%   3,295 34 %   4,613 3,099 49 %
Gold COS (Barrick’s share)a,c ($/oz) 1,993 1,922 4 %   1,654 20 %   1,959 1,641 19 %
Gold TCCa,b ($/oz) 1,426 1,327 7 %   1,239 15 %   1,378 1,229 12 %
Gold AISCa,b ($/oz) 1,866 1,708 9 %   1,684 11 %   1,790 1,728 4 %
Revenue ($ millions)a 3,612 3,683 (2)%   2,575 40 %   7,295 4,790 52 %
Attributable adjusted EBITDA ($ millions)b 2,168 2,481 (13)%   1,424 52 %   4,649 2,556 82 %

Copper
                   
Copper production (thousands of tonnes)a 56 49 14 %   59 (5)%   105 103 2 %
Copper sold (thousands of tonnes)a 54 45 20 %   54 0 %   99 105 (6)%
Market copper price ($/lb) 6.05 5.83 4 %   4.32 40 %   5.93 4.28 39 %
Realized copper pricea,b ($/lb) 6.15 5.79 6 %   4.36 41 %   5.99 4.43 35 %
Copper COS (Barrick’s share)a,d ($/lb) 3.39 3.41 (1)%   2.56 32 %   3.40 2.74 24 %
Copper C1 cash costsa,b ($/lb) 2.47 2.57 (4)%   1.80 37 %   2.52 2.02 25 %
Copper AISCa,b ($/lb) 3.95 3.67 8 %   2.90 36 %   3.82 2.98 28 %
Revenue ($ millions)a 697 557 25 %   484 44 %   1,254 958 31 %
Attributable adjusted EBITDA ($ millions)b 377 280 35 %   266 42 %   657 495 33 %

a. On an attributable basis.
b. Further information on these non-GAAP financial measures, including detailed reconciliations, is included in the endnotes to this press release.
c. Gold COS/oz is calculated as cost of sales across our gold operations (excluding sites in closure or care and maintenance) divided by ounces sold (both on an attributable basis using Barrick’s ownership share).
d. Copper COS/lb is calculated as cost of sales across our copper operations divided by pounds sold (both on an attributable basis using Barrick’s ownership share).
   

Regional Summary

a

and 2026 Guidance

b

  For the three months ended   For the six months ended   2026
Guidance
  6/30/26 3/31/26 6/30/25   6/30/26 6/30/25  
Gold                
North America                
Gold produced (000s oz) 494 457 508   951 962   1,770 – 1,980
Gold sold (000s oz) 494 462 501   956 961    
COS ($/oz)d 1,900 1,783 1,701   1,843 1,694   1,820 – 2,010
TCC ($/oz)c 1,330 1,213 1,299   1,274 1,286   1,270 – 1,410
AISC ($/oz)c 1,729 1,612 1,714   1,673 1,776   1,690 – 1,870
Revenue ($ millions) 2,234 2,253 1,671   4,487 3,026    
Attributable adjusted EBITDA ($ millions)c 1,352 1,552 886   2,904 1,556    
South America & Asia Pacific                
Gold produced (000s oz) 59 74 85   133 177   630 – 730
Gold sold (000s oz) 68 76 91   144 180    
COS ($/oz)d 2,031 1,773 1,266   1,896 1,266   1,490 – 1,590
TCC ($/oz)c 1,247 1,126 828   1,183 859   940 – 1,020
AISC ($/oz)c 1,597 1,393 1,325   1,490 1,346   1,430 – 1,530
Revenue ($ millions) 317 377 304   694 568    
Attributable adjusted EBITDA ($ millions)c 197 262 234   459 390    
Africa & Middle East                
Gold produced (000s oz) 243 188 204   431 416   820 – 910
Gold sold (000s oz) 239 210 178   449 380    
COS ($/oz)d 2,175 2,281 1,718   2,225 1,676   1,420 – 1,520
TCC ($/oz)c 1,662 1,633 1,277   1,649 1,260   1,060 – 1,140
AISC ($/oz)c 2,039 1,836 1,577   1,944 1,591   1,360 – 1,460
Revenue ($ millions) 1,061 1,053 600   2,114 1,196    
Attributable adjusted EBITDA ($ millions)c 619 667 304   1,286 610    
Total Gold                
Gold produced (000s oz) 796 719 797   1,515 1,555   2,900 – 3,250
Gold sold (000s oz) 801 748 770   1,549 1,521    
COS ($/oz)d 1,993 1,922 1,654   1,959 1,641   1,870 – 2,070
TCC ($/oz)c 1,426 1,327 1,239   1,378 1,229   1,330 – 1,470
AISC ($/oz)c 1,866 1,708 1,684   1,790 1,728   1,760 – 1,950
Revenue ($ millions) 3,612 3,683 2,575   7,295 4,790    
Attributable adjusted EBITDA ($ millions)c 2,168 2,481 1,424   4,649 2,556    
Total Copper                
Copper produced (kt) 56 49 59   105 103   190 – 220
Copper sold (kt) 54 45 54   99 105    
COS ($/lb)e 3.39 3.41 2.56   3.40 2.74   3.05 – 3.35
C1 cash costs ($/lb)c 2.47 2.57 1.80   2.52 2.02   2.20 – 2.45
AISC ($/lb)c 3.95 3.67 2.90   3.82 2.98   3.45 – 3.75
Revenue ($ millions) 697 557 484   1,254 958    
Attributable adjusted EBITDA ($ millions)c 377 280 266   657 495    

a. All figures in this table are on an attributable basis.
b. See “Outlook Assumptions and Economic Sensitivity Analysis” in endnote 6 of this press release.
c. Further information on these non-GAAP financial measures, including detailed reconciliations, is included in endnote 3 of this press release.
d. Gold COS/oz is calculated as cost of sales across our gold operations (excluding sites in closure or care and maintenance) divided by ounces sold (both on an attributable basis using Barrick’s ownership share).
e. Copper COS/lb is calculated as cost of sales across our copper operations divided by pounds sold (both on an attributable basis using Barrick’s ownership share).
   

Technical Information

The scientific and technical information contained in this press release has been reviewed and approved by Richard Peattie, MPhil, FAusIMM, Chief Technical Officer; Sam Baldwin, Vice President Geology, MSc, MAIG; Joel Holliday, FAusIMM, Executive Vice President, Exploration; and Jesse Clark, BSc (Hons), MSc, RM SME, Vice President, Geology—each a “Qualified Person” as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

All mineral reserve and mineral resource estimates are estimated in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Unless otherwise noted, such mineral reserve and mineral resource estimates are as of December 31, 2025.

Endnotes

Endnote 1

On an attributable basis.

Endnote
2

On an attributable basis. Gold COS/oz is calculated as cost of sales across our gold operations (excluding sites in closure or care and maintenance) divided by ounces sold (both on an attributable basis using Barrick’s ownership share).

Endnote
3
– Non-GAAP Financial Measures

Total cash costs per ounce and All-in sustaining costs per ounce

“Total cash costs” per ounce (TCC/oz) and “All-in sustaining costs” per ounce (AISC/oz) are non-GAAP financial measures which are calculated based on the definition published by the World Gold Council (a market development organization for the gold industry comprised of and funded by gold mining companies from around the world, including Barrick, the “WGC”). The WGC is not a regulatory organization. Management uses these measures to monitor the performance of our gold mining operations and their ability to generate positive cash flow, both on an individual site basis and an overall company basis. TCC/oz starts with our cost of sales related to gold production and removes depreciation, the non-controlling interest of cost of sales and costs allocated to by-products. AISC/oz start with TCC/oz and includes sustaining capital expenditures, sustaining leases, general and administrative costs, minesite exploration and evaluation costs related to the current mine plan and reclamation cost accretion and amortization. Barrick believes that the use of TCC/oz and AISC/oz will assist analysts, investors and other stakeholders of Barrick in understanding the costs associated with producing gold, understanding the economics of gold mining, assessing our operating performance and also our ability to generate free cash flow from the gold operations portion of our business. Due to the capital-intensive nature of the industry and the long useful lives over which these items are depreciated, there can be a significant timing difference between net earnings calculated in accordance with IFRS and the amount of free cash flow that is generated by a mine and therefore Barrick believes these measures are useful non-GAAP operating metrics and supplement our IFRS disclosures. These measures are not representative of all of Barrick’s cash expenditures as they do not include income tax payments, interest costs or dividend payments. These measures do not include depreciation or amortization. TCC/oz and AISC/oz are intended to provide additional information only and do not have standardized definitions under IFRS and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. These measures are not equivalent to net income or cash flow from operations as determined under IFRS. Although the WGC has published a standardized definition, other companies may calculate these measures differently. Further details on these non-GAAP financial measures are provided in the MD&A accompanying Barrick’s financial statements filed from time to time on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. The following table reconciles these non-GAAP financial measures to the most directly comparable IFRS measure.

Reconciliation of Gold Cost of Sales to Total cash costs and All-in sustaining costs, including on a per ounce basis

($ millions, except per oz information in dollars)    For the three months ended For the six months ended
  Footnote 6/30/26 3/31/26 6/30/25 6/30/26 6/30/25
COS applicable to gold production   2,109   1,874   1,676   3,983   3,244  
Depreciation   (478 ) (449 ) (359 ) (927 ) (701 )
Total cash costs applicable to equity method investments   130   128   101   258   210  
Costs allocated to by-products   (128 ) (119 ) (64 ) (247 ) (124 )
Other a (8 ) (33 ) 11   (41 ) 16  
Non-controlling interests b (484 ) (409 ) (411 ) (893 ) (775 )
Total cash costs   1,141   992   954   2,133   1,870  
General & administrative costs   31   39   39   70   81  
Minesite exploration and evaluation costs c 4   4   7   8   12  
Minesite sustaining capital expenditures d 500   380   479   880   1,043  
Sustaining leases   2   6   7   8   15  
Rehabilitation – accretion and amortization (operating sites) e 17   16   16   33   33  
Non-controlling interest, copper operations and other f (201 ) (159 ) (208 ) (360 ) (425 )
All-in sustaining costs   1,494   1,278   1,294   2,772   2,629  
Ounces sold – attributable basis (koz) g 801   748   770   1,549   1,521  
COS/oz h,i 1,993   1,922   1,654   1,959   1,641  
TCC/oz i 1,426   1,327   1,239   1,378   1,229  
AISC/oz i 1,866   1,708   1,684   1,790   1,728  

a. Other – Other adjustments mainly relate to treatment and refining charges.
b. Non-controlling interests – Non-controlling interests include non-controlling interests related to gold production of $682 million and $1,282 million for Q2 2026 and YTD 2026 respectively, (Q1 2026: $600 million; Q2 2025: $540 million, YTD 2025: $1,027 million). Non-controlling interests include NGM, Pueblo Viejo, Loulo-Gounkoto, Tongon, North Mara and Bulyanhulu. Refer to Note 5 to the Financial Statements for further information.
c. Exploration and evaluation costs – Exploration, evaluation and project expenses are included in AISC if they support current mine operations.
d. Capital expenditures – Capital expenditures are related to our gold sites only and are split between minesite sustaining and project capital expenditures.
e. Rehabilitation—accretion and amortization – Includes depreciation on the assets related to rehabilitation provisions of our gold operations and accretion on the rehabilitation provision of our gold operations, split between operating and non-operating sites.
f. Non-controlling interest and copper operations  – Removes general and administrative costs related to non-controlling interests and copper based on a percentage allocation of revenue. Also removes exploration, evaluation and project expenses, rehabilitation costs and capital expenditures incurred by our copper sites and the non-controlling interests related to NGM, Pueblo Viejo, Loulo-Gounkoto, Tongon, North Mara and Bulyanhulu operating segments. It also includes capital expenditures applicable to our equity method investment in Kibali. The impact is summarized as the following:
   

  ($ millions) For the three months ended For the six months ended
  Non-controlling interest, copper operations and other 6/30/26 3/31/26 6/30/25 6/30/26 6/30/25
  General & administrative costs (5 ) (6 ) (6 ) (11 ) (12 )
  Minesite exploration and evaluation expenses (1 ) (1 ) (3 ) (2 ) (3 )
  Rehabilitation – accretion and amortization (operating sites) (9 ) (5 ) (6 ) (14 ) (11 )
  Minesite sustaining capital expenditures (186 ) (147 ) (193 ) (333 ) (399 )
  All-in sustaining costs total (201 ) (159 ) (208 ) (360 ) (425 )

g.  Ounces sold – attributable basis – Excludes Long Canyon which is producing residual ounces from the leach pad while in care and maintenance.
h. COS/oz – Gold COS/oz is calculated as cost of sales across our gold operations (excluding sites in closure or care and maintenance) divided by ounces sold (both on an attributable basis using Barrick’s ownership share).
i. Per ounce figures – COS/oz, TCC/oz and AISC/oz may not calculate based on amounts presented in this table due to rounding.
   

Free Cash Flow, Attributable Free Cash Flow and Attributable Operating Cash Flow

“Free cash flow” is a non-GAAP financial measure that deducts capital expenditures from net cash provided by operating activities. “Attributable free cash flow” starts with free cash flow and adds our attributable share of free cash flow from our equity investees and subtracts the free cash flow attributable to the non-controlling interests. Management believes these to be useful indicators of our ability to operate without reliance on additional borrowing or usage of existing cash. “Attributable operating cash flow” starts with cash provided by operating activities and adds our attributable share of cash provided by operating activities from our equity investees and subtracts the cash provided by operating activities attributable to the non-controlling interests. Management believes this to be a useful indicator of the amount of cash provided by operating activities to Barrick’s ownership share. Free cash flow, attributable free cash flow and attributable operating cash flow are intended to provide additional information only and do not have any standardized definitions under IFRS, and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. These measures are not necessarily indicative of operating profit or cash flow from operations as determined under IFRS. Other companies may calculate these measures differently. Further details on these non-GAAP financial measures are provided in the MD&A accompanying Barrick’s financial statements filed from time to time on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. The following table reconciles these non-GAAP financial measures to the most directly comparable IFRS measure.

Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow, Attributable Free Cash Flow and Attributable Operating Cash Flow

($ millions) For the three months ended For the six months ended
  6/30/26 3/31/26 6/30/25 6/30/26 6/30/25
Net cash provided by operating activities 1,704   2,554   1,329   4,258   2,541  
Capital expenditures (1,189 ) (979 ) (934 ) (2,168 ) (1,771 )
Free cash flow (consolidated) 515   1,575   395   2,090   770  
Free cash flow applicable to equity investees 113   330   66   443   222  
Non-controlling interests (487 ) (692 ) (249 ) (1,179 ) (557 )
Attributable free cash flow 141   1,213   212   1,354   435  
Attributable capital expenditures 978   755   717   1,733   1,348  
Attributable operating cash flow 1,119   1,968   929   3,087   1,783  
                     

Adjusted Net Earnings and Adjusted Net Earnings per Share

“Adjusted net earnings” and “adjusted net earnings per share” are non-GAAP financial measures. Adjusted net earnings excludes the following from net earnings: impairment charges (reversals) related to intangibles, goodwill, property, plant and equipment, and investments; acquisition/disposition gains/losses; foreign currency translation gains/losses; significant tax adjustments; other items that are not indicative of the underlying operating performance of our core mining business; and tax effect and non-controlling interest of the above items. Management uses this measure internally to evaluate our underlying operating performance for the reporting periods presented and to assist with the planning and forecasting of future operating results. Management believes that adjusted net earnings is a useful measure of our performance because impairment charges, acquisition/disposition gains/losses and significant tax adjustments do not reflect the underlying operating performance of our core mining business and are not necessarily indicative of future operating results. Furthermore, foreign currency translation gains/losses are not necessarily reflective of the underlying operating results for the reporting periods presented. The tax effect and non-controlling interest of the adjusting items are also excluded to reconcile the amounts to Barrick’s shares on a post-tax basis, consistent with net earnings. Adjusted net earnings and adjusted net earnings per share are intended to provide additional information only and do not have standardized definitions under IFRS and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The measures are not necessarily indicative of operating profit or cash flow from operations as determined under IFRS. Other companies may calculate these measures differently. The following table reconciles these non-GAAP financial measures to the most directly comparable IFRS measure. Further details on these non-GAAP financial measures are provided in the MD&A accompanying Barrick’s financial statements filed from time to time on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

Reconciliation of Net Earnings to Net Earnings per Share, Adjusted Net Earnings and Adjusted Net Earnings per Share

($ millions, except per share amounts in dollars) For the three months ended For the six months ended
  6/30/26 3/31/26 6/30/25 6/30/26 6/30/25
Net earnings attributable to equity holders of the Company 1,217   1,602   811   2,819   1,285  
Impairment charges related to intangibles, goodwill, property, plant and equipment, and investmentsa (1 )     (1 ) 4  
Acquisition/disposition (gains) lossesb (10 ) 1   289   (9 ) 289  
(Gain) loss on currency translation 14   20   (2 ) 34    
Significant tax adjustmentsc (6 ) 35   (35 ) 29   (50 )
Other expense adjustmentsd 236   18   44   254   217  
Non-controlling interest (77 ) (8 ) (4 ) (85 ) (15 )
Tax effecte (10 ) (20 ) (303 ) (30 ) (327 )
Adjusted net earnings 1,363   1,648   800   3,011   1,403  
Net earnings per sharef 0.73   0.96   0.47   1.69   0.75  
Adjusted net earnings per sharef 0.82   0.98   0.47   1.80   0.82  

a. There were no significant impairment charges or reversals in the current period or prior periods.
b. Acquisition/disposition (losses) gains for Q2 2025 and YTD 2025 mainly relate to the net loss of $1,035 million on the deconsolidation of Loulo-Gounkoto following the change of control after it was placed under a temporary provisional administration on June 16, 2025 (refer to note 4 of the Financial Statements for further details), partially offset by the recognition of our investment in Loulo-Gounkoto. This was offset by a gain of $745 million on the sale of our 50% interest in the Donlin Gold project.
c. Significant tax adjustments for Q2 2026 and YTD 2026 primarily include adjustments in respect of prior years, the re-measurement of current and deferred tax balances and the impact of uncertain tax positions. Significant tax adjustments for Q2 2025 and YTD 2025 include the re-measurement of deferred tax balances and adjustments in respect of prior years. The significant tax adjustments presented include the re-measurement of current and deferred tax balances and the impact of uncertain tax positions.
d. Other expense for Q2 2026 and YTD 2026 period mainly related to additional royalties, penalties and interest related to the retrospective application of the 2023 Mining Code to Loulo-Gounkoto for 2024 and 2025 combined with the fair value increment on inventory resulting from the purchase price allocation when we regained control of Loulo-Gounkoto, remobilization costs at Mali, legal and consulting costs related to our North America IPO project and revaluation of contingent consideration for Hemlo. Other expense adjustments for the 2025 periods mainly relate to reduced operation costs at Loulo-Gounkoto, and also include the signing of agreements to settle legacy legal matters in the Philippines related to Placer Dome Inc.
e. Tax effect for Q2 2026 and YTD 2026 mainly relates to other expense adjustments. For Q2 2025 and YTD 2025 tax effect primarily relates to acquisition/disposition losses (gains).
f. Calculated using the weighted average number of shares outstanding under the basic method of earnings per share.
   

C1 cash costs per pound and All-in sustaining costs per pound

“C1 cash costs” per pound (C1 cash costs/lb) and “All-in sustaining costs” per pound (AISC/lb) are non-GAAP financial measures related to our copper mine operations. Barrick believes that C1 cash costs/lb enables investors to better understand the performance of our copper operations in comparison to other copper producers who present results on a similar basis. C1 cash costs/lb excludes royalties, production taxes and non-routine charges as they are not direct production costs. AISC/lb is similar to the gold AISC metric and management uses this to better evaluate the costs of copper production. Barrick believes this measure enables investors to better understand the operating performance of our copper mines as this measure reflects all of the sustaining expenditures incurred in order to produce copper. AISC/lb includes C1 cash costs, sustaining capital expenditures, sustaining leases, general and administrative costs, minesite exploration and evaluation costs, royalties, production taxes, reclamation cost accretion and amortization and writedowns taken on inventory to net realizable value. Further details on these non-GAAP financial measures are provided in the MD&A accompanying Barrick’s financial statements filed from time to time on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. The following table reconciles these non-GAAP financial measures to the most directly comparable IFRS measure.

Reconciliation of Copper Cost of Sales to C1 cash costs and All-in sustaining costs, including on a per pound basis

($ millions, except per lb information in dollars) For the three months ended For the six months ended
   6/30/26 3/31/26 6/30/25 6/30/26 6/30/25
Cost of sales 280   217   193   497   401  
Depreciation/amortization (71 ) (43 ) (68 ) (114 ) (128 )
Treatment and refinement charges 49   35   40   84   82  
C1 cash costs applicable to equity method investments 95   95   84   190   174  
Less: royalties (43 ) (30 ) (25 ) (73 ) (46 )
Costs allocated to by-products (15 ) (18 ) (12 ) (33 ) (17 )
C1 cash costs of sales 295   256   212   551   466  
General & administrative costs 6   6   8   12   16  
Rehabilitation – accretion and amortization 1   1   3   2   4  
Royalties 43   30   25   73   46  
Minesite exploration and evaluation costs 3   2   1   5   3  
Minesite sustaining capital expenditures 120   66   90   186   147  
Sustaining leases 2   1   2   3   5  
All-in sustaining costs 470   362   341   832   687  
Tonnes sold – attributable basis (thousands of tonnes) 54   45   54   99   105  
Pounds sold – attributable basis (millions pounds) 119   99   118   218   231  
COS/lb

a,b
3.39   3.41   2.56   3.40   2.74  
C1 cash costs per pound

a
2.47   2.57   1.80   2.52   2.02  
AISC/lb

a
3.95   3.67   2.90   3.82   2.98  

a. COS/lb, C1 cash costs/lb and AISC/lb may not calculate based on amounts presented in this table due to rounding.
b. Copper COS/lb is calculated as cost of sales across our copper operations divided by pounds sold (both on an attributable basis using Barrick’s ownership share).
   

EBITDA, Adjusted EBITDA, Attributable Adjusted EBITDA, Attributable Adjusted EBITDA Margin and Net Leverage

EBITDA is a non-GAAP financial measure, which excludes the following from net earnings: income tax expense; finance costs; finance income; and depreciation. Management believes that EBITDA is a valuable indicator of our ability to generate liquidity by producing operating cash flow to fund working capital needs, service debt obligations, and fund capital expenditures. Management uses EBITDA for this purpose. Adjusted EBITDA removes the effect of impairment charges; acquisition/disposition gains/losses; foreign currency translation gains/losses; and other expense adjustments. Barrick also removes the impact of the income tax expense, finance costs, finance income and depreciation incurred in our equity method accounted investments. Attributable Adjusted EBITDA further removes the non-controlling interest portion. Barrick believes these items provide a greater level of consistency with the adjusting items included in our adjusted net earnings reconciliation, with the exception that these amounts are adjusted to remove any impact on finance costs/income, income tax expense and/or depreciation as they do not affect EBITDA. Barrick believes this additional information will assist analysts, investors and other stakeholders of Barrick in better understanding our ability to generate liquidity from our attributable business, including equity method investments, by excluding these amounts from the calculation as they are not indicative of the performance of our core mining business and do not necessarily reflect the underlying operating results for the periods presented. Additionally, it is aligned with how Barrick presents our forward-looking guidance on gold ounces and copper pounds produced. Attributable Adjusted EBITDA margin is calculated as attributable adjusted EBITDA divided by revenues – as adjusted. Barrick believes this ratio will assist analysts, investors and other stakeholders of Barrick to better understand the relationship between revenues and EBITDA or operating profit. Net leverage is calculated as debt, net of cash divided by the sum of adjusted EBITDA of the last four consecutive quarters. Barrick believes this ratio will assist analysts, investors and other stakeholders of Barrick in monitoring our leverage and evaluating our balance sheet. EBITDA, adjusted EBITDA, attributable adjusted EBITDA, EBITDA margin and net leverage are intended to provide additional information to investors and analysts and do not have any standardized definition under IFRS, and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. EBITDA, adjusted EBITDA and attributable adjusted EBITDA exclude the impact of cash costs of financing activities and taxes, and the effects of changes in operating working capital balances, and therefore are not necessarily indicative of operating profit or cash flow from operations as determined under IFRS. Other companies may calculate EBITDA, adjusted EBITDA, attributable adjusted EBITDA, EBITDA margin and net leverage differently. Further details on these non-GAAP financial measures are provided in the MD&A accompanying Barrick’s financial statements filed from time to time on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. The following table reconciles these non-GAAP financial measures to the most directly comparable IFRS measure.

Reconciliation of Net Earnings to EBITDA, Adjusted EBITDA and Attributable Adjusted EBITDA

($ millions) For the three months ended For the six months ended
   6/30/26 3/31/26 6/30/25 6/30/26 6/30/25
Net earnings 1,892   2,481   1,256   4,373   2,037  
Income tax expense 732   747   102   1,479   380  
Finance costs, neta 6   19   36   25   75  
Depreciation 555   500   436   1,055   847  
EBITDA 3,185   3,747   1,830   6,932   3,339  
Impairment charges of non-current assetsb (1 ) 0   0   (1 ) 4  
Acquisition/disposition losses (gains)c (10 ) 1   289   (9 ) 289  
(Gain) loss on currency translation 14   20   (2 ) 34   0  
Other expense adjustmentsd 236   18   44   254   217  
Income tax expense, net finance costsa and depreciation from equity investees 204   148   156   352   297  
Adjusted EBITDA 3,628   3,934   2,317   7,562   4,146  
Non-controlling Interests (1,083 ) (1,173 ) (627 ) (2,256 ) (1,095 )
Attributable adjusted EBITDA 2,545   2,761   1,690   5,306   3,051  
Revenues – as adjustede 4,267   4,181   3,050   8,448   5,735  
Attributable adjusted EBITDA marginf 60 % 66 % 55 % 63 % 53 %
  As at 6/30/26 As at 12/31/25 As at 6/30/25 As at 6/30/26 As at 12/31/25
Net leverageg -0.1:1 -0.2:1 0.0:1 -0.1:1 -0.2:1

a. Finance costs exclude accretion.
b. There were no significant impairment charges or reversals in the current period or prior periods.
c. Acquisition/disposition gains for Q4 2025 relate to gain on sale of our Hemlo gold mine, our interest in the Tongon gold mine and the Alturas project. Q4 2025 was further impacted by the accounting impact of regaining control of the Loulo-Gounkoto complex on December 16, 2025.
d. Other expense for Q2 2026 and YTD 2026 period mainly related to additional royalties, penalties and interest related to the retrospective application of the 2023 Mining Code to Loulo-Gounkoto for 2024 and 2025 combined with the fair value increment on inventory resulting from the purchase price allocation when we regained control of Loulo-Gounkoto, remobilization costs at Mali, legal and consulting costs related to our North America IPO project and revaluation of contingent consideration for Hemlo. Other expense adjustments for the 2025 periods mainly relate to reduced operation costs at Loulo-Gounkoto, and also include the signing of agreements to settle legacy legal matters in the Philippines related to Placer Dome Inc.
e. Refer to Reconciliation of Sales to Realized Price per oz/pound on the next page of this press release.
f. Represents attributable adjusted EBITDA divided by revenues – as adjusted.
g. Represents debt, net of cash divided by adjusted EBITDA of the last four consecutive quarters.
   

Capital Expenditures

These amounts are presented on the same basis as our guidance. Minesite sustaining capital expenditures and project capital expenditures are non-GAAP financial measures. Capital expenditures are classified into minesite sustaining capital expenditures or project capital expenditures depending on the nature of the expenditure. Minesite sustaining capital expenditures is the capital spending required to support current production levels. Project capital expenditures represent the capital spending at new projects and major, discrete projects at existing operations intended to increase net present value through higher production or longer mine life. Management believes this to be a useful indicator of the purpose of capital expenditures and this distinction is an input into the calculation of all-in sustaining costs per ounce/pound. Classifying capital expenditures is intended to provide additional information only and does not have any standardized definition under IFRS, and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Other companies may calculate these measures differently. Further details on these non-GAAP financial measures are provided in the MD&A accompanying Barrick’s financial statements filed from time to time on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. The following table reconciles these non-GAAP financial measures to the most directly comparable IFRS measure.

Reconciliation of the Classification of Capital Expenditures

($ millions) For the three months ended   For the six months ended
  6/30/26 3/31/26 6/30/25   6/30/26 6/30/25
Minesite sustaining capital expenditures 500 380 479   880 1,043
Project capital expenditures 654 570 439   1,224 708
Capitalized interest 35 29 16   64 20
Total consolidated capital expenditures 1,189 979 934   2,168 1,771
             

Realized Price

“Realized price” is a non-GAAP financial measure which excludes from sales: treatment and refining charges; and cumulative catch-up adjustment to revenue relating to our streaming arrangements. Barrick believes this provides investors and analysts with a more accurate measure with which to compare to market gold and copper prices and to assess our gold and copper sales performance. For those reasons, management believes that this measure provides a more accurate reflection of our Company’s past performance and is a better indicator of its expected performance in future periods. The realized price measure is intended to provide additional information, and does not have any standardized definition under IFRS and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The measure is not necessarily indicative of sales as determined under IFRS. Other companies may calculate this measure differently. Further details on these non-GAAP financial measures are provided in the MD&A accompanying Barrick’s financial statements filed from time to time on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. The following table reconciles realized prices to the most directly comparable IFRS measure.

Reconciliation of Sales to Realized Price per ounce/pound

($ millions, except per oz/lb information in dollars)

Gold Copper Gold Copper
For the three months ended For the six months ended
   6/30/26 3/31/26 6/30/25 6/30/26 3/31/26 6/30/25 6/30/26 6/30/25 6/30/26 6/30/25
Sales 4,665   4,756   3,280   499 343 337 9,421   6,046   842 641
Sales applicable to non-controlling interests (1,553 ) (1,591 ) (1,054 ) 0 0 0 (3,144 ) (1,902 ) 0 0
Sales applicable to equity method investmentsa,b 416   446   306   182 196 135 862   558   378 299
Sales applicable to sites in closure or care and maintenancec (2 ) (13 )   0 0 0 (15 ) (2 ) 0 0
Treatment and refinement charges 11   9   7   49 35 40 20   13   84 82
Otherd 0   0   0   0 0 0 0   0   0 0
Revenues – as adjusted 3,537   3,607   2,538   730 574 512 7,144   4,713   1,304 1,022
Ounces/pounds sold (koz/Mlb)c 801   748   770   119 99 118 1,549   1,521   218 231
Realized gold/copper price per oz/lbe 4,417   4,823   3,295   6.15 5.79 4.36 4,613   3,099   5.99 4.43

a. Represents sales of $313 million for Q2 2026 and YTD 2026 $654 million (Q1 2026: $341 million; Q2 2025: $226 million; YTD 2025: $417 million) applicable to our 45% equity method investment in Kibali and $103 million for Q2 2026 and YTD 2026 $208 million (Q1 2026: $105 million; Q2 2025: $80 million; YTD 2025 $141 million) applicable to our 24.5% equity method investment in Porgera for gold. Represents sales of $123 million for Q2 2026 and YTD 2026 $233 million (Q1 2026: $110 million; Q2 2025: $71 million; YTD 2025: $166 million) applicable to our 50% equity method investment in Zaldívar and $60 million and $146 million respectively (Q1 2026: $86 million; Q2 2025: $65 million; YTD 2025: $137 million), applicable to our 50% equity method investment in Jabal Sayid for copper.
b. Sales applicable to equity method investments are net of treatment and refinement charges.
c. On an attributable basis. Excludes Long Canyon which is producing residual ounces from the leach pad while in care and maintenance.
d. Represents cumulative catch-up adjustment to revenue relating to our streaming arrangements. Refer to note 2e of the 2025 Annual Financial Statements for more information.
e. Realized price per oz/lb may not calculate based on amounts presented in this table due to rounding.
   

Endnote 
4

On an attributable basis. Copper COS/lb is calculated as cost of sales across our copper operations divided by pounds sold (both on an attributable basis using Barrick’s ownership share).

Endnote
5

A Tier One Gold Asset is an asset with a $1,500/oz reserve with potential to deliver a minimum 10-year life, annual production of at least 500,000 ounces of gold and with projected costs per ounce in the lower half of the industry cost curve. A Tier One Copper Asset/Project is an asset with a $3.25/lb reserve with potential for +5Mt contained copper in support at least 20 years life, annual production of at least 200ktpa, with costs per pound in the lower half of the industry cost curve. Tier One Assets must be located in a world-class geological district with potential for organic reserve growth and long-term geologically driven addition.

Endnote
6
– 2026 Outlook Assumptions and Economic Sensitivity Analysis

  2026 guidance assumption Hypothetical change Consolidated impact on EBITDA (millions) Attributable impact on EBITDA3 (millions) Attributable impact on TCC3 and AISC3
Gold price sensitivity $4,500/oz +/- $100/oz +/-$390 +/-$270 +/-$5/oz
Copper price sensitivity $5.50/lb +/-$0.25/lb +/- $110 +/- $110 +/-$0.01/lb
Oil prices $70/bbl WTI
$75/bbl Brent
+/- $10/bbl +/- $61 +/- $56 +/- $12/oz

Key Outlook Assumptions 2026
Gold price ($/oz) 4,500
Copper price ($/lb) 5.50
Oil price (WTI) ($/barrel) 70
Oil price (Brent) ($/barrel) 75
AUD exchange rate (AUD:USD) 0.75
ARS exchange rate (USD:ARS) 1,513
CAD exchange rate (USD:CAD) 1.30
CLP exchange rate (USD:CLP) 900
EUR exchange rate (EUR:USD) 1.10

Cautionary Statement on Forward-Looking Information

Certain information contained or incorporated by reference in this press release, including any information as to our strategy, projects, plans or future financial or operating performance, constitutes “forward-looking statements”. All statements, other than statements of historical fact, are forward-looking statements. The words “believe”, “expect”, “plan”, “committed”, “guidance”, “project”, “continue”, “progress”, “develop”, “on track”, “target”, “estimate”, “growth”, “potential”, “future”, “will”, “could”, “would”, “should”, “may” and similar expressions identify forward-looking statements. In particular, this press release contains forward-looking statements including, without limitation, with respect to: Barrick’s forward-looking production guidance; estimates of future cost of sales per ounce for gold and per pound for copper, total cash costs per ounce and C1 cash costs per pound, and all-in sustaining costs per ounce/pound; projected capital, operating and exploration expenditures; our ability to convert resources into reserves and replace reserves net of depletion from production; mine life and production rates, including anticipated production growth from Barrick’s organic project pipeline; the potential for Fourmile to become a standalone Tier One Gold Asset; Barrick’s global exploration strategy and planned exploration activities; Barrick’s copper strategy; our plans, and expected timing, completion and benefits of our growth projects, including the Lumwana Super Pit Expansion project; potential mineralization and metal or mineral recoveries; Barrick’s dividend policy; Barrick’s intention to pursue and the expected timing for and potential benefits of an IPO of Barrick’s North American gold assets; the structure and the ability of the IPO to generate significant value for Barrick and its Joint Venture partner; and expectations regarding future price assumptions, financial performance and other outlook or guidance.

Forward-looking statements are necessarily based upon a number of estimates and assumptions including material estimates and assumptions related to the factors set forth below that, while considered reasonable by the Company as at the date of this press release in light of management’s experience and perception of current conditions and expected developments, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements and undue reliance should not be placed on such statements and information. Such factors include, but are not limited to: fluctuations in the spot and forward price of gold, copper or certain other commodities (such as silver, diesel fuel, natural gas and electricity); risks associated with projects in the early stages of evaluation and for which additional engineering and other analysis is required; risks related to the possibility that future exploration results will not be consistent with the Company’s expectations, that quantities or grades of reserves will be diminished, and that resources may not be converted to reserves; risks associated with the fact that certain of the initiatives described in this press release are still in the early stages and may not materialize; changes in mineral production performance, exploitation and exploration successes; risks that exploration data may be incomplete and considerable additional work may be required to complete further evaluation, including but not limited to drilling, engineering and socioeconomic studies and investment; the speculative nature of mineral exploration and development; lack of certainty with respect to foreign legal systems, corruption and other factors that are inconsistent with the rule of law; changes in national and local government legislation, taxation, controls or regulations and/or changes in the administration of laws, policies and practices; expropriation or nationalization of property and political or economic developments in Canada, the United States, or other countries in which Barrick does or may carry on business in the future; risks relating to the proposed IPO of an entity that will hold Barrick’s North American assets; risks relating to political instability in certain of the jurisdictions in which Barrick operates; timing of receipt of, or failure to comply with, necessary permits and approvals; non-renewal of key licenses by governmental authorities; failure to comply with environmental and health and safety laws and regulations; increased costs and physical and transition risks related to climate change, including extreme weather events, resource shortages, emerging policies and increased regulations related to greenhouse gas (“GHG”) emission levels, energy efficiency and reporting of risks; the Company’s ability to achieve its sustainability goals, including its climate-related goals and GHG emissions reduction targets; contests over title to properties, particularly title to undeveloped properties, or over access to water, power and other required infrastructure; the liability associated with risks and hazards in the mining industry, and the ability to maintain insurance to cover such losses; damage to the Company’s reputation due to the actual or perceived occurrence of any number of events, including negative publicity with respect to the Company’s handling of environmental matters or dealings with community groups, whether true or not; risks related to operations near communities that may regard Barrick’s operations as being detrimental to them; litigation and legal and administrative proceedings; operating or technical difficulties in connection with mining or development activities, including geotechnical challenges, tailings dam and storage facilities failures, and disruptions in the maintenance or provision of required infrastructure and information technology systems; increased costs, delays, suspensions and technical challenges associated with the construction of capital projects; risks associated with working with partners in jointly controlled assets; risks related to disruption of supply routes which may cause delays in construction and mining activities, including disruptions in the supply of key mining inputs due to the invasion of Ukraine by Russia and conflicts in the Middle East; risk of loss due to acts of war, terrorism, sabotage and civil disturbances; risks associated with artisanal and illegal mining; risks associated with Barrick’s infrastructure, information technology systems and the implementation of Barrick’s technological initiatives, including risks related to cybersecurity incidents, including those caused by computer viruses, malware, ransomware and other cyberattacks, or similar information technology system failures, delays and/or disruptions; the impact of global liquidity and credit availability on the timing of cash flows and the values of assets and liabilities based on projected future cash flows; the impact of inflation, including global inflationary pressures driven by ongoing global supply chain disruptions, global energy cost increases following the invasion of Ukraine by Russia and country-specific political and economic factors in Argentina and uncertainty related to Venezuela; adverse changes in our credit ratings; fluctuations in the currency markets; changes in U.S. dollar interest rates; changes in U.S. trade, tariff and other controls on imports and exports, tax, immigration or other policies that may impact relations with foreign countries, result in retaliatory policies, lead to increased costs for raw materials and components, or impact Barrick’s existing operations and material growth projects; risks arising from holding derivative instruments (such as credit risk, market liquidity risk and mark-to-market risk); risks related to the demands placed on the Company’s management, the ability of management to implement its business strategy and enhanced political risk in certain jurisdictions; uncertainty whether some or all of Barrick’s targeted investments and projects will meet the Company’s capital allocation objectives and internal hurdle rate; whether benefits expected from recent transactions are realized; business opportunities that may be presented to, or pursued by, the Company; our ability to successfully integrate acquisitions or complete divestitures; risks related to competition in the mining industry; employee relations including loss of key employees; availability and increased costs associated with mining inputs and labor; risks associated with diseases, epidemics and pandemics; risks related to the failure of internal controls; and risks related to the impairment of the Company’s goodwill and assets.

In addition, there are risks and hazards associated with the business of mineral exploration, development and mining, including environmental hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins, flooding and gold bullion, copper cathode or gold or copper concentrate losses (and the risk of inadequate insurance, or inability to obtain insurance, to cover these risks).

Many of these uncertainties and contingencies can affect our actual results and could cause actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, us. Readers are cautioned that forward-looking statements are not guarantees of future performance. All of the forward-looking statements made in this press release are qualified by these cautionary statements. Specific reference is made to the most recent Form 40-F/ Annual Information Form on file with the SEC and Canadian provincial securities regulatory authorities for a more detailed discussion of some of the factors underlying forward-looking statements and the risks that may affect Barrick’s ability to achieve the expectations set forth in the forward-looking statements contained in this press release. We disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.



BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers

Regional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets

SAN CARLOS, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)–BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets.

Clinical collaboration will explore potential targeted combination approaches for patients with RAS-addicted cancers

Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zoldonrasib, a RAS(ON) G12D-selective inhibitor; elironrasib, a RAS(ON) G12C-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor. Planned combination studies include: BeOne’s MTA-cooperative PRMT5 inhibitor, BGB-58067, and an EGFR x MET x MET trispecific antibody, BG-T187, with either daraxonrasib or zoldonrasib.

Regional rights agreement leverages BeOne’s established R&D and commercial expertise and Revolution Medicines’ clinical stage RAS(ON) inhibitor portfolio

Under the regional rights agreement, Revolution Medicines has granted BeOne exclusive rights in select Asian markets to develop and commercialize or solely commercialize, depending on the market, these four clinical-stage RAS(ON) inhibitors. Revolution Medicines is eligible to receive development and sales milestone payments and tiered royalties on net sales in the partnered region. Revolution Medicines retains development and commercial rights to all its assets outside of the licensed territory, including Japan and South Korea. As part of this multi-part arrangement, BeOne will fund and conduct a global registrational Phase 3 study for one of Revolution Medicines RAS(ON) inhibitors using BeOne’s differentiated, fully in-house development superhighway, while Revolution Medicines continues to advance a broad range of global registrational studies across its portfolio.

John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:

“We are pleased to enter this collaboration with Revolution Medicines, which gives BeOne the opportunity to evaluate combinations between assets from our oncology pipeline and four promising RAS(ON) inhibitors from Revolution Medicines. In parallel, the regional rights transaction allows us to use our global development superhighway capabilities and established commercial presence, with the goal of bringing more medicines to patients with difficult-to-treat cancers.”

Mark A. Goldsmith, M.D., Ph.D., CEO and Chairman of Revolution Medicines, said:

“This arrangement with BeOne reflects our commitment to advancing RAS(ON) inhibitors for patients with RAS-addicted cancers around the world, including in regions where we have not previously had a presence, while exploring novel combination strategies that may further expand their potential impact. BeOne brings additional established global oncology development capabilities and a strong regional commercial footprint that can help us broaden the reach of our innovative RAS(ON) inhibitors as part of our ambitious global strategy.”

About BeOne

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.

To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

About Revolution Medicines

Revolution Medicines is a late-stage clinical oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.

For more information, please visit www.revmed.com.

BeOne Medicines Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s and Revolution Medicines’ plans, expectations and goals for their strategic collaboration and regional rights transaction; the potential to evaluate and develop combination therapies involving select BeOne assets and Revolution Medicines’ RAS(ON) inhibitors; BeOne’s development and commercialization activities in select Asian markets; Revolution Medicines’ global portfolio strategy; and the potential benefits of the agreement for patients with RAS-addicted cancers. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including each company’s ability to: successfully execute its obligations under the agreement; demonstrate the efficacy and safety of its drug candidates; generate clinical results that support further development or marketing approval; obtain regulatory approvals and achieve commercial success, if approved; obtain and maintain intellectual property protection; rely on third parties for drug development, manufacturing, commercialization and other services; and other risks more fully discussed in each company’s filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and neither company undertakes any duty to update such information unless required by law.

Revolution Medicines Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding Revolution Medicines plan to evaluate and develop combination therapies through the collaboration with BeOne Medicines, including potential combinations, funding and expected benefits from any such development; milestone payments, sales milestone payments and tiered royalties on net sales that Revolution Medicines may receive under the collaboration with BeOne Medicines; Revolution Medicines’ development opportunities, plans and timelines and its ability to build or advance its portfolio and R&D pipeline; the progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of Revolution Medicines’ candidates being studied; Revolution Medicines’ ability to discover and develop approaches that improve outcomes for patients with RAS-addicted cancers; and plans for developing any of Revolution Medicines’ product candidates as part of a combination treatment.

Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “potential,” “project,” “up to,” “will” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause Revolution Medicines’ development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Revolution Medicines’ programs’ development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, commercialization preparation and launch readiness, Revolution Medicines’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Revolution Medicines’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on Revolution Medicines’ business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

BeOne Medicines Media & Investor Contacts:

Investor Contact

Liza Heapes

+1 857-302-5663

[email protected]

Media Contact

Kyle Blankenship

+1 667-351-5176

[email protected]

To access BeOne media resources, please visit ourNewsroom.

Revolution Medicines Media & Investor Contacts:

[email protected]

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Research Clinical Trials Other Health Biotechnology General Health Pharmaceutical Health Science Oncology Other Science

MEDIA:

Logo
Logo

AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results

Same Center Cases Up 1% for the Second Consecutive Quarter

MIAMI BEACH, Fla., Aug. 10, 2026 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the second quarter ended June 30, 2026.

Yogi Jashnani, Chief Executive Officer, stated: “In the second quarter, we advanced our key priorities — delivering our second quarter of stability. During the quarter, we stepped up our investment in marketing and advanced our plans to introduce new, sought-after procedures including entering an exclusive partnership with AlloClae that expands our treatment offering and enhances our body contouring platform.”

“We enter the second half of the year a fundamentally stronger company with the right strategy and team. Our addressable market is larger, our procedure mix is broader, and our operating platform is more disciplined than it was twelve months ago,” concluded Mr. Jashnani.

Second Quarter and First Six Months 2026 (“YTD”) Highlights

  • Positive Business Momentum:
    • Grew same center case volume 1.0% and 1.1%, in Q2 2026 and YTD, respectively versus prior year;
    • Achieved stable same center sales in Q2 2026 and YTD, respectively versus prior year; and
    • Delivered flat same center sales YTD.
  • Advanced Strategic Priorities:
    • Introduced new services to broaden service offering – including first-ever partnership with AlloClae to offer an innovative injectable adipose matrix that broadens AirSculpt’s addressable patient population;
    • Increased awareness with brand marketing;
    • Improved Financial Flexibility since the start of 2025;
      • Reduction in gross debt of ~$30 million to $44.2 million; and
      • Increased cash by ~$10mm to $18.8 million.

Second Quarter 2026 Results

  • Case volume was 3,376 for the second quarter of 2026, representing a (0.5)% decrease from the fiscal year 2025 second quarter case volume of 3,392
  • Revenue declined (3)% to $42.9 million from $44.0 million in the fiscal year 2025;
  • Net loss for the quarter was $1.1 million compared to net loss of $0.6 million in the fiscal year 2025 second quarter; and
  • Adjusted EBITDA was $4.9 million compared to $5.8 million in the fiscal year 2025 second quarter.

First Six Months 2026 Results

  • Case volume was 6,458 for the first six months of 2026, representing a (0.2)% decrease from the first six months of 2025 case volume of 6,468
  • Revenue declined 1.3% to $82.3 million from $83.4 million in the first six months of fiscal year 2025;
  • Net loss was $3.5 million compared to $3.4 million in the first six months of fiscal year 2025; and
  • Adjusted EBITDA was $8.2 million compared to $9.6 million in the first six months of fiscal year 2025.

2026 Outlook

The Company is reaffirming its full year 2026 revenue at the lower end of its guidance range of approximately $151 to $157 million and reducing its adjusted EBITDA outlook to the range of approximately $12 to $14 million.

For additional information on forward-looking statements, see the section titled “Forward-Looking Statements” below.

Debt & Liquidity

As of June 30, 2026, the Company had $18.8 million in cash and cash equivalents, with $5.0 million of borrowing capacity under its revolving credit facility. Additionally, gross debt was approximately $44.2 million. During the 2026 second quarter, the Company raised an additional $5.0 million from the at-the-market offering program and paid down $1.4 million of debt.

On August 7, 2026, the Company entered into an amended term loan agreement that extends its maturity to November 2027. In connection with the amendment, the Company made a $2.5 million term loan payment at signing and is required to make an additional $2.5 million payment on or before September 30, 2026. The Amendment also requires that 50% of the net proceeds of future equity issuances (other than under the Company’s equity incentive plans) be applied to prepay the term loans.

Conference Call Information

AirSculpt will hold a conference call today, August 10, 2026 at 8:30 am (Eastern Time). The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13761751 or by visiting the link below to request a return call for instant telephone access to the event.

https://callme.viavid.com/viavid/?callme=true&passcode=13725116&h=true&info=company&r=true&B=6

The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days following the call.

To learn more about AirSculpt, please visit the Company’s website at https://investors.airsculpt.com. AirSculpt uses its website as a channel of distribution for material Company information. Financial and other material information regarding AirSculpt is routinely posted on the Company’s website and is readily accessible.

About AirSculpt

AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal U.S. securities laws. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include projections of our future financial performance (including in particular our projected 2026 revenue and adjusted EBITDA), our anticipated growth strategies, and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. You are cautioned that there are important risks and uncertainties, many of which are beyond our control, that could cause our actual results, level of activity, performance, or achievements to differ materially from the projected results, level of activity, performance or achievements that are expressed or implied by such forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements, including those factors discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K.

Our future results could be affected by a variety of other factors, including, but not limited to, inability to sell equity or other securities in the future at a time when we might otherwise wish to effect sales; inability to raise capital on commercially reasonable terms, if at all; the risk that any future financings may dilute our stockholders or restrict our business; failure to stabilize same-store performance; not being able to optimize our marketing investment, go-to-market strategy and sales process; not having the ability to expand our financing options for consumers; being unsuccessful in further product innovations; failure to operate centers in a cost-effective manner; increased operating expenses due to rising inflation; increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability and customer awareness of weight-loss drugs; shortages or quality control issues with third-party manufacturers or suppliers; competition for surgeons; litigation or medical malpractice claims; inability to protect the confidentiality of our proprietary information; changes in the laws governing the corporate practice of medicine or fee-splitting; changes in regulatory and macroeconomic conditions, including inflation and the threat of recession, economic and other conditions of the states and jurisdictions where our facilities are located; and business disruption or other losses from natural disasters, war, pandemic, terrorist acts or political unrest.

The risk factors discussed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K and in other filings we make from time to time with the SEC could cause our results to differ materially from those expressed in the forward-looking statements made in this press release.

There also may be other risks and uncertainties that are currently unknown to us or that we are unable to predict at this time.

Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Forward-looking statements represent our estimates and assumptions only as of the date they were made, which are inherently subject to change, and we are under no duty and we assume no obligation to update any of these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated after the date of this press release to conform our prior statements to actual results or revised expectations, except as required by law. Given these uncertainties, investors should not place undue reliance on these forward-looking statements.

Use of Non-GAAP Financial Measures

The Company reports financial results in accordance with generally accepted accounting principles in the United States (“GAAP”), however, the Company believes the evaluation of ongoing operating results may be enhanced by a presentation of Comparable Net Revenue, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Loss and Adjusted Net Loss per Share, which are non-GAAP financial measures. Although the Company provides guidance for Adjusted EBITDA, it is not able to provide guidance for net income, the most directly comparable GAAP measure. Certain elements of the composition of net income, including equity-based compensation, are not predictable, making it impractical for us to provide guidance on net income or to reconcile our Adjusted EBITDA guidance to net income without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information regarding net income, which could be material to future results.

These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with GAAP. Rather, they are presented as supplemental measures of the Company’s performance that management believes may enhance the evaluation of the Company’s ongoing operating results. These non-GAAP financial measures are not presented in accordance with GAAP, and the Company’s computation of these non-GAAP financial measures may vary from similar measures used by other companies. These measures have limitations as an analytical tool and should not be considered in isolation or as a substitute or alternative to revenue, net income, operating income, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP.

AirSculpt Technologies, Inc. and Subsidiaries

Selected Consolidated Financial Data

(Dollars in thousands, except shares and per share amounts)
       
  Three Months Ended

June 30,
  Six Months Ended

June 30,
    2026       2025       2026       2025  
Revenue $ 42,900     $ 44,012     $ 82,289     $ 83,383  
Operating expenses:              
Cost of service   16,567       17,201       32,155       33,151  
Selling, general and administrative   23,421       22,671       46,003       44,439  
Depreciation and amortization   2,941       3,246       5,962       6,488  
Loss on impairment of long-lived assets         108             108  
Total operating expenses   42,929       43,226       84,120       84,186  
(Loss)/income from operations   (29 )     786       (1,831 )     (803 )
Interest expense, net   1,043       1,562       2,241       3,187  
Unrealized loss   141             3        
Pre-tax net loss   (1,213 )     (776 )     (4,075 )     (3,990 )
Income tax benefit   (101 )     (185 )     (566 )     (552 )
Net loss $ (1,112 )   $ (591 )   $ (3,509 )   $ (3,438 )
               
Loss per share of common stock              
Basic $ (0.02 )   $ (0.01 )   $ (0.05 )   $ (0.06 )
Diluted $ (0.02 )   $ (0.01 )   $ (0.05 )   $ (0.06 )
Weighted average shares outstanding              
Basic   70,786,163       59,590,033       70,127,093       59,066,400  
Diluted   70,786,163       59,590,033       70,127,093       59,066,400  

AirSculpt Technologies, Inc. and Subsidiaries

Selected Financial and Operating Data

(Dollars in thousands, except per case amounts)
       
  June 30,

2026
  December 31,
2025
Balance Sheet Data (at period end):      
Cash and cash equivalents $ 18,824   $ 8,449
Total current assets   27,496     15,456
Total assets $ 193,281   $ 187,304
       
Current portion of long-term debt $ 10,460   $ 5,460
Deferred revenue and patient deposits   3,149     1,871
Total current liabilities   34,949     27,902
Long-term debt, net   33,108     50,585
Total liabilities $ 88,449   $ 99,592
       
Total stockholders’ equity $ 104,832   $ 87,712

  Three Months Ended

June 30,
  Six Months Ended

June 30,
    2026       2025       2026       2025  
Cash Flow Data:              
Net cash provided by (used in):              
Operating activities $ (1,238 )   $ 4,984     $ 4,033     $ 5,852  
Investing activities   (228 )     (265 )     (279 )     (2,166 )
Financing activities   3,600       (2,083 )     6,621       (3,732 )

  Three Months Ended

June 30,
  Six Months Ended

June 30,
    2026       2025       2026       2025  
Other Data:              
Number of facilities   31       32       31       32  
Number of total procedure rooms   65       67       65       67  
               
Cases   3,376       3,392       6,458       6,468  
Revenue per case $ 12,707     $ 12,975     $ 12,742     $ 12,892  
Adjusted EBITDA(1) $ 4,937     $ 5,835     $ 8,248     $ 9,590  
Adjusted EBITDA margin(2)   11.5%       13.3%       10.0%       11.5%  

(1) A reconciliation of this non-GAAP financial measure appears below.
(2) Defined as Adjusted EBITDA as a percentage of revenue.

  Three Months Ended

June 30,
  Six Months Ended

June 30,
    2026       2025     2026       2025
Same-center Information

(1)

:
             
Cases   3,376       3,341     6,458       6,389
Case growth   1.0%     N/A     1.1%     N/A
Revenue per case $ 12,707     $ 12,971   $ 12,742     $ 12,889
Revenue per case growth (2.0)%     N/A   (1.1)%     N/A
Number of facilities   31       31     31       31
Number of total procedure rooms   65       65     65       65

(1) For the three and six months ended June 30, 2026 and 2025, we define same-center case and revenue growth as the growth in each of our cases and revenue at facilities that were owned and operated during the three and six months ended June 30, 2026 and 2025, respectively. At facilities that were not owned or operated for the entirety of the prior year period, the current year period has been pro-rated to reflect only growth experienced during the portion of the three and six months ended June 30, 2026 in which such facilities were owned and operated during the three and six months ended June 30, 2025. We define same-center facilities and procedure rooms based on if a facility was owned or operated as of June 30, 2025. We have excluded the London facility from all periods presented due to the closure of the facility.
   

AirSculpt Technologies, Inc. and Subsidiaries

Reconciliation of Non-GAAP Financial Measures

(Dollars in thousands)

We report our financial results in accordance with GAAP, however, management believes the evaluation of our ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Loss and Adjusted Net Loss per Share, which are non-GAAP financial measures.

We define Adjusted EBITDA as net loss excluding depreciation and amortization, net interest expense, income tax benefit, restructuring and related severance costs, certain other non-recurring costs, unrealized (gain)/loss, and equity-based compensation.

We define Adjusted Net Loss as net loss excluding restructuring and related severance costs, certain other non-recurring costs, equity-based compensation and the tax effect of these adjustments.

We include Adjusted EBITDA and Adjusted Net Loss because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA and Adjusted Net Loss each to be an important measure because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA has limitations as an analytical tool including: (i) Adjusted EBITDA does not include results from equity-based compensation and (ii) Adjusted EBITDA does not reflect interest expense on our debt or the cash requirements necessary to service interest or principal payments. Adjusted Net Loss has limitations as an analytical tool because it does not include results from equity-based compensation.

We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of revenue. We define Adjusted Net Loss per Share as Adjusted Net Loss divided by weighted average basic and diluted shares. We included Adjusted EBITDA Margin and Adjusted Net Loss per Share because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA Margin and Adjusted Net Loss per Share to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis.

The following table reconciles Adjusted EBITDA and Adjusted EBITDA Margin to net loss, the most directly comparable GAAP financial measure:

  Three Months Ended

June 30,
  Six Months Ended

June 30,
    2026       2025       2026       2025  
Net loss $ (1,112 )   $ (591 )   $ (3,509 )   $ (3,438 )
Plus            
Equity-based compensation   912       1,352       1,471       2,591  
Restructuring and related severance costs   323       343       1,276       1,206  
One-time SOX compliance and other related costs   465             1,046        
Depreciation and amortization   2,941       3,246       5,962       6,488  
Loss on impairment of long-lived assets         108             108  
Litigation settlements   325             325        
Interest expense, net   1,043       1,562       2,241       3,187  
Income tax benefit   (101 )     (185 )     (566 )     (552 )
Unrealized loss   141             3        
Adjusted EBITDA $ 4,937     $ 5,835     $ 8,248     $ 9,590  
Adjusted EBITDA Margin   11.5 %     13.3 %     10.0 %     11.5 %
                               

The following table reconciles Adjusted Net Loss and Adjusted Net Loss per Share to net loss, the most directly comparable GAAP financial measure:

  Three Months Ended

June 30,
  Six Months Ended

June 30,
    2026       2025       2026       2025  
Net loss $ (1,112 )   $ (591 )   $ (3,509 )   $ (3,438 )
Plus              
Equity-based compensation   912       1,352       1,471       2,591  
Restructuring and related severance costs   323       343       1,276       1,206  
Loss on impairment of long-lived assets         108             108  
Cost related to closing location, net                    
Litigation settlements   325             325      
One-time SOX compliance and other related costs   465             1,046      
Tax effect of adjustments   (304 )     (25 )     (820 )     (388 )
Adjusted net (loss)/income $ 609     $ 1,187     $ (211 )   $ 79  
               
Adjusted net loss per share of common stock(1)              
Basic $ 0.01     $ 0.02     $ 0.00     $ 0.00  
Diluted $ 0.01     $ 0.02     $ 0.00     $ 0.00  
Weighted average shares outstanding              
Basic   70,786,163       59,590,033       70,127,093       59,066,400  
Diluted   70,981,004       60,379,884       70,127,093       59,802,603  

(1) Diluted Adjusted Net Loss Per Share is computed by dividing adjusted net loss by the weighted-average number of shares of common stock outstanding adjusted for the dilutive effect of all potential shares of common stock.
   

Investor Contact

Allison Malkin
ICR, Inc.
[email protected]



BRC Inc. Announces 1-for-10 Reverse Stock Split

BRC Inc. Announces 1-for-10 Reverse Stock Split

SALT LAKE CITY–(BUSINESS WIRE)–
BRC Inc. (NYSE: BRCC) (“Black Rifle Coffee Company” or the “Company”), a Veteran-founded, mission-driven premium coffee company, today announced that the Company expects to effect a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s Class A common stock and Class B common stock on August 21, 2026 (the “Effective Date”).

The Reverse Stock Split of the Class A common stock is expected to become effective at 5:01 p.m. Eastern Time on the Effective Date (the “Class A Effective Time”), and the Reverse Stock Split of the Class B common stock is expected to become effective at 5:02 p.m. Eastern Time on the Effective Date (the “Class B Effective Time”), upon the filing and effectiveness of certificates of amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. The Company’s Class A common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange when the market opens on August 24, 2026 under the existing trading symbol, “BRCC.” The new CUSIP number for the Class A common stock following the Reverse Stock Split will be 05601U204.

The Reverse Stock Split of the Company’s Class A common stock was approved by the Company’s stockholders at its 2026 Annual Meeting of Stockholders, held on May 28, 2026 (the “Annual Meeting”), with the final ratio determined thereafter by the Company’s board of directors (the “Board”). Holders of a majority of the shares of Class B common stock previously approved the Reverse Stock Split of the Company’s Class B common stock, subject to approval of the reverse stock split amendments set forth in the proxy statement for the Annual Meeting by the holders of Class A common stock. The Board approved the 1-for-10 Reverse Stock Split on August 7, 2026.

“We are confident in the strength of our brand, our strategy and our long-term opportunity. We believe long-term shareholder value will be driven by disciplined execution, operating efficiency, profitable growth and continued progress against our strategic priorities,” said Matt Amigh, Chief Financial Officer of Black Rifle Coffee Company. “The reverse stock split is a proactive structural action intended to support continued compliance with NYSE listing standards and better position our share price to meet the investment criteria and minimum share-price thresholds used by certain institutional investors. This action does not change our strategy, operations or business priorities.”

Reverse Stock Split Mechanics

At the Class A Effective Time, every 10 shares of Class A common stock issued and outstanding immediately before the Class A Effective Time will automatically be reclassified into one share of Class A common stock. At the Class B Effective Time, every 10 shares of Class B common stock issued and outstanding immediately before the Class B Effective Time will automatically be reclassified into one share of Class B common stock.

Except for adjustments resulting from the treatment of fractional shares, the Reverse Stock Split will affect all holders of each class proportionately and will not change any stockholder’s percentage ownership interest, voting rights or other rights associated with the Company’s common stock.

The par value of both the Class A common stock and Class B common stock will remain $0.0001 per share. The Reverse Stock Split will not reduce the number of shares of capital stock the Company is authorized to issue.

Proportionate adjustments will be made to the number of shares underlying the Company’s outstanding equity-based awards, the number of shares available for issuance under the Company’s equity compensation plans and the exercise prices, stock-price goals and other per-share terms applicable to those awards, in accordance with the applicable plans and award agreements.

Treatment of Fractional Shares

No fractional shares or scrip will be issued in connection with the Reverse Stock Split.

Continental Stock Transfer & Trust Company (“Continental”), the Company’s transfer agent, will aggregate the fractional shares of Class A common stock that otherwise would have been issued and sell those shares in the open market at the then-prevailing price as soon as practicable after the Class A Effective Time. Holders otherwise entitled to receive a fractional share of Class A common stock will instead receive a cash payment from Continental representing their proportionate share of the proceeds from that sale.

As soon as practicable after the Class B Effective Time, holders otherwise entitled to receive a fractional share of Class B common stock will receive a cash payment from the Company equal to the closing price of the Company’s Class A common stock on the NYSE on the Effective Date multiplied by the fractional share of Class B common stock the holder otherwise would have been entitled.

The treatment of fractional shares may have tax consequences. Stockholders should consult their own tax advisors regarding their individual circumstances.

Information for Stockholders

Registered stockholders who hold their shares electronically in book-entry form are not required to take any action to receive their post-split shares. Stockholders who hold shares through a bank, broker or other nominee will have their positions adjusted in accordance with that institution’s procedures and should contact the institution with any questions.

Additional information regarding the Reverse Stock Split is included in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 10, 2026.

About Black Rifle Coffee Company

Black Rifle Coffee Company (BRCC) is a Veteran-founded premium coffee company and lifestyle brand serving beverages to people who love America. Founded in 2014 by Green Beret Evan Hafer, Black Rifle develops its explosive coffee roast profiles with the same mission focus learned while serving in the military. BRCC is committed to supporting Veterans, active-duty military, first responders, and the American way of life.

To learn more, visit www.blackriflecoffee.com, subscribe to the BRCC newsletter, or follow along on social media.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements about the Company that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this press release, including statements regarding the effective times of the Reverse Stock Split, the trading of the Company’s Class A common stock on a split-adjusted basis, the Company’s ability to continue to build long-term shareholder value, the expansion of the range of institutional investors able to consider the Company’s shares under their investment guidelines as a result of the Reverse Stock Split and the Company’s ability to continue to comply with all applicable listing standards of the NYSE, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “continue,” “can,” “intend,” “may,” “plan,” “possible,” “potential,” “predict,” “should,” “will,” “would” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. The events and circumstances reflected in the Company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Factors that may cause such forward-looking statements to differ from actual results include, but are not limited to: the Company’s ability to continue to comply with the NYSE listing standards and to maintain the listing of the Company’s Class A common stock, and other risks and uncertainties indicated in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on March 2, 2026 including those set forth under “Item 1A. Risk Factors” included therein, as well as in our other filings with the SEC. Such forward-looking statements are based on information available as of the date of this press release and the Company’s current beliefs and expectations concerning future developments and their effects on the Company and speak only as of the date of this press release. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

For inquiries regarding Black Rifle Coffee Company:

Investors: [email protected]

Press: [email protected]

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Retail Restaurant/Bar Food/Beverage

MEDIA:

TJGC Group Limited in Negotiations for AI and Robotics Technology License

HONG KONG, Aug. 10, 2026 (GLOBE NEWSWIRE) — TJGC Group Limited (Nasdaq: TJGC) (the “Company”) today announced it is negotiating a potential intellectual property license agreement with a robotics technology provider. The parties hope to enter into a definitive agreement granting the Company non-exclusive, worldwide rights to commercialize certain artificial intelligence and robotics technologies in intelligent automation products.

The Company stated that the potential license aligns with its intelligent automation strategy and would enhance its technology portfolio. There is no assurance the parties will reach a definitive agreement.

About TJGC Group Limited

TJGC Group Limited, through its subsidiary, Ctrl Media Limited provides integrated marketing and advertising services in Hong Kong. The company offers services to mobile game developers, principally developers of mobile gaming applications that gamers download from the developers’ websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store. It also uses digital media, such as online social media platforms, websites, and search engines over the Internet to broadcast the advertising campaigns. In addition, the company undertakes contracts with YouTuber, KOL, and local celebrities to film introductory gaming videos for broadcast in their personal blogs and social media platforms; offers physical media, including podium platforms with transportation terminals and public venues to broadcast advertising campaigns; and assists clients to plan and prepare their exhibition booths in the animation-comic-game and other offline marketing events. The company was formerly known as Ctrl Group Limited and change its name to TJGC Group Limited in November 2025. TJGC Group Limited was incorporated in 2022 and is based in Hung Hom, Hong Kong.

Forward Looking-Statements

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,”“believe,”“continue,”“could,”“estimate,”“expect,”“intend,”“may,”“plan,”“potential,”“predict,”“project,”“should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the final prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and TJGC specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

For more information, please contact:

Investor Relations
Ctrl Media Limited
Phone: +852-3107-4887
Email: [email protected]



Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to January 31, 2027 which is approximately 76 months from the date of the Company’s IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company’s common stock unless otherwise modified by the Board of Directors. After January 31, 2027, the quantity of these locked-up shares that can be sold daily and over various periods of time will be restricted under a leak-out plan unless otherwise modified by the Board of Directors.

The Board could choose to end all or a small percentage of the 100% lock-up at any time for any reason, including prior to any data announcements, interim analyses, strategic transactions, such as an acquisition or partnership, or financial transactions, such as royalty or strategic investor transactions that provide a potential bridge to commercialization. The Board could also choose to implement a pre-determined leak-out plan and/or a 10b5-1 selling program at any time for any reason that allows for the organized independent selling of some of the locked-up shares by a third party over a specified period of time. Such decisions may or may not be announced at the time of the board’s decision.

CEO Snehal Patel commented, “We attended and presented at the BIO conference in June 2026 and plan to attend the BIO-Europe conference later this year, where strategic and financing transactions can be originated or concluded. With the further derisking of the Phase III clinical trial, more than doubling of enrollment and event rate, interest from leading clinicians and hospitals in up to 200 sites in the US and Europe, screening of over 1,500 patients, and the transformation of the interim analysis into a big pharma like study similar in design to recent large breast cancer studies, we are expecting a continued up-tick in the quantity and seriousness of such discussions.”

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Greenwich LifeSciences’ Annual Report on the most recent Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact

Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: [email protected]

Investor & Public Relations Contact for Greenwich LifeSciences

Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: [email protected]